Synnovation Therapeutics
PrivateLast Round
Series A
Jan 24, 2024
Total Funding Raised
$147M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Synnovation Therapeutics operates in Healthcare & Life Sciences and is based in Wilmington, Delaware. Its latest recorded funding round was a Series A round in January 2024.
Synnovation Therapeutics is a biotechnology company that develops precision small molecule therapies for the treatment of cancer and immunological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Synnovation Therapeutics Comparables
Compare Synnovation Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Duke Street Bio | 89% | |
| 1cBio, Inc. | 87% | |
| Idience Co., Ltd. | 83% |
For institutional investors. Book with your work email.
Synnovation Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 24, 2024 | ||||
| Series A | May 24, 2023 | ||||
| Seed | Nov 24, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Synnovation Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sirona Capital | Series A |
| Cormorant Asset Management | Series A |
| Lilly Asia Ventures | Series A |
| Nextech Invest | Series A |
| Lilly Asia Ventures | Series A |
| Cormorant Asset Management | Series A |
| Third Rock Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 134% MoM, reaching 3.5K.
- Apr 28, 2026
Acquired Excellergy Inc. for $2 billion.
For institutional investors. Book with your work email.
Synnovation Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Synnovation Therapeutics's valuation, stock price, and market status.
Is Synnovation Therapeutics a public or private company?
Synnovation Therapeutics is a private company.
What is the current stock price of Synnovation Therapeutics?
Synnovation Therapeutics is a private company, so its shares have no public market price. Caplight tracks Synnovation Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Synnovation Therapeutics worth (valuation)?
Valuation information for Synnovation Therapeutics is not publicly available.
Can I buy Synnovation Therapeutics stock?
Synnovation Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Synnovation Therapeutics's last funding round?
Synnovation Therapeutics's most recent funding round was Series A on January 24, 2024.
Who are the main investors in Synnovation Therapeutics?
Key investors in Synnovation Therapeutics include Third Rock Ventures.
Will Synnovation Therapeutics IPO soon?
No public IPO plans have been announced for Synnovation Therapeutics.
How can I track Synnovation Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Synnovation Therapeutics's shares on secondary markets.